TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17526629

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Bupropion Sustained Release (SR)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 149

Group type: COMPARATOR
Intervention: General findings
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Smoking cessation influence on alcohol use
Number of subjects: 149
Study: 15030818

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12139592

Group type: COMPARATOR
Intervention: N2O/O2‐fentanyl
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40
Study: 10357331

Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone 20 mg every 12 h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate-release oxycodone 10 mg every 4 h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate-release oxycodone 10 mg every 4 h as needed
Number of subjects: 0
Study: 7892519

Group type: EXPERIMENTAL
Intervention: Daily alcohol intake and nutrient intake
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Carbohydrates intake
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Saturated lipid intake
Number of subjects: 282

Group type: COMPARATOR
Intervention: Alcohol consumption (more than 100 g ethanol per day)
Number of subjects: 282
Study: 1974100

Group type: EXPERIMENTAL
Intervention: 5 mg carvedilol i.v.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 333997

Group type: EXPERIMENTAL
Intervention: Single dose of 0.5 mg terbutaline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Two consecutive doses of 0.25 mg terbutaline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Four consecutive doses of 0.125 mg terbutaline
Number of subjects: 12
Study: 31180608

Group type: EXPERIMENTAL
Intervention: Middle Cerebral Artery (MCA) Doppler evaluation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Umbilical Artery (UA) Doppler evaluation
Number of subjects: 20
Study: 29211735

Group type: EXPERIMENTAL
Intervention: Directed patrol by uniformed, unarmed security agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control stations (no directed patrol)
Number of subjects: 0
Study: 24499166

Group type: EXPERIMENTAL
Intervention: Egitromb 300 mg at admission followed by 8 days of 75 mg Egitromb daily (Group A, n = 28)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Plavix 300 mg at admission followed by 8 days of 75 mg Plavix daily (Group B, n = 25)
Number of subjects: 53
Study: 23907506

Group type: EXPERIMENTAL
Intervention: Cell phone-based intervention
Number of subjects: 474

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 474
Study: 22184293

Group type: COMPARATOR
Intervention: Intraperitoneal normal saline infusion (INSI)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Pulmonary recruitment maneuver (PRM)
Number of subjects: 158
Study: 19336358

Group type: EXPERIMENTAL
Intervention: Multimicronutrient supplementation (5 minerals and 10 vitamins at levels approximating the recommended daily allowance)
Number of subjects: 5828

Group type: COMPARATOR
Intervention: Folic acid plus iron supplementation
Number of subjects: 5828

Group type: COMPARATOR
Intervention: Folic acid supplementation
Number of subjects: 5828
Study: 16397156

Group type: EXPERIMENTAL
Intervention: Community agency survey
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Community agency resources and programming
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Partnerships involving community agencies
Number of subjects: 138
Study: 15069729

Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg/d for 5 days
Number of subjects: 57

Group type: COMPARATOR
Intervention: Metronidazole 500 mg, three times a day for 5 days
Number of subjects: 57
Study: 11960045

Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Medical evacuation
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Surgical evacuation
Number of subjects: 82

Group type: COMPARATOR
Intervention: All methods
Number of subjects: 82
Study: 9842842

Group type: EXPERIMENTAL
Intervention: Clonidine (0.3 mg/d skin patch and 0.6 mg oral loading dose 60-90 min before surgery)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (patches and pills)
Number of subjects: 64
Study: 7662197

Group type: EXPERIMENTAL
Intervention: Surgeons in Zambia
Number of subjects: 7

Group type: COMPARATOR
Intervention: Surgeons in western hospitals
Number of subjects: 7
Study: 2756515

Group type: EXPERIMENTAL
Intervention: Cicletanine 50 mg/day
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Cicletanine 100 mg/day
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Cicletanine 150 mg/day
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 412646

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate moulded tablet ('Nitrostat')
Number of subjects: 13

Group type: COMPARATOR
Intervention: Generic compressed tablet
Number of subjects: 13
Study: 30646205

Group type: EXPERIMENTAL
Intervention: IIDEA treatment (10 sessions)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 341
Study: 29364743

Group type: EXPERIMENTAL
Intervention: I-Gel airway (IGA)
Number of subjects: 19

Group type: COMPARATOR
Intervention: King Laryngotracheal airway (KA)
Number of subjects: 19
Study: 27159403

Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 193

Group type: COMPARATOR
Intervention: Normotensive controls
Number of subjects: 193
Study: 24444287

Group type: EXPERIMENTAL
Intervention: Immediate intrauterine contraception (IUC) placement post-abortion
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Delayed intrauterine contraception (IUC) placement four weeks post-abortion
Number of subjects: 1500
Study: 22930176

Group type: EXPERIMENTAL
Intervention: MiroCam
Number of subjects: 50

Group type: COMPARATOR
Intervention: EndoCapsule
Number of subjects: 50
Study: 20420121

Group type: EXPERIMENTAL
Intervention: Non-locked H-plate system with autogeneous cancellous bone (155 trauma patients)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Non-locked H-plate system with tricortical autograft (167 patients)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Locked cervical plate system with tricortical autograft (73 patients)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Standalone cages filled with autolog cortico-spongiosus bone chips (90 patients)
Number of subjects: 485
Study: 18030180

Group type: EXPERIMENTAL
Intervention: Pharmacological treatments for chronic diseases
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Counting pill intake
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Qualitative measure of adherence (adherent patient, yes/no)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Proportion of treatment prescribed
Number of subjects: 192
Study: 15691301

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 295

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 295
Study: 12046348

Group type: EXPERIMENTAL
Intervention: SA gene A1A2 polymorphism in women with PIH
Number of subjects: 124
Study: 10036952

Group type: EXPERIMENTAL
Intervention: One-week treatment with LPZ 30 mg once daily, AMPC 1500 mg twice daily, CAM 800 mg twice daily
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Two-week treatment with LPZ 30 mg once daily, AMPC 1500 mg twice daily, CAM 800 mg twice daily
Number of subjects: 106
Study: 7575314

Group type: EXPERIMENTAL
Intervention: 0.25 mg triazolam (TRZ)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 8
Study: 2109286

Group type: EXPERIMENTAL
Intervention: Cyclosporin alone
Number of subjects: 72

Group type: COMPARATOR
Intervention: Cyclosporin with pulse methylprednisolone for rejection
Number of subjects: 72

Group type: COMPARATOR
Intervention: Azathioprine and prednisolone
Number of subjects: 72
Study: 6989067

Group type: EXPERIMENTAL
Intervention: HRE (isoniazid, rifampicin, ethambutol) for 2 months followed by H2R2 (isoniazid and rifampicin twice weekly) for 4 months
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: HRSZ (isoniazid, rifampicin, streptomycin, pyrazinamide) for 2 months followed by 4HRE (isoniazid, rifampicin, ethambutol daily) for 4 months
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: H1R1E1 or H2R2 (isoniazid, rifampicin, ethambutol intermittently) for 4 months
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Pyrazinamide included in the initial phase of treatment
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Overall treatment regimens (6 months)
Number of subjects: 530
Study: 31580094

Group type: EXPERIMENTAL
Intervention: Nietos Activos y Saludables intervention (4 weekly sessions)
Number of subjects: 12
Study: 27705075

Group type: EXPERIMENTAL
Intervention: Physioball between knees
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Elastic band around knees
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control protocol (4 LP sets without intervention)
Number of subjects: 18
Study: 27063626

Group type: EXPERIMENTAL
Intervention: Daclizumab high-yield process (DAC HYP) 150mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24241508

Group type: EXPERIMENTAL
Intervention: Stroke-specific follow-up care model (5 home visits by a stroke care coordinator over 18 months)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 117
Study: 21932067

Group type: EXPERIMENTAL
Intervention: Selective family-focused intervention
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Universal intervention
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Combination of interventions
Number of subjects: 1062

Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 1062
Study: 19261962

Group type: EXPERIMENTAL
Intervention: Pharmacist's intervention to improve medication adherence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prescription refill adherence measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cut-point of 80% for defining nonadherence
Number of subjects: 0
Study: 17707822

Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 56

Group type: COMPARATOR
Intervention: TVT
Number of subjects: 56
Study: 16361729

Group type: EXPERIMENTAL
Intervention: Topical oxytetracycline hydrochloride (tetracycline)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Combination of topical tetracycline and oral antibiotics
Number of subjects: 49
Study: 12530759

Group type: EXPERIMENTAL
Intervention: Experimental group receiving suggestive information
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study: 9605061

Group type: EXPERIMENTAL
Intervention: Intravenous ergotamine (0.25 mg)
Number of subjects: 15
Study: 10160046

Group type: EXPERIMENTAL
Intervention: Strong social support for not smoking
Number of subjects: 1110

Group type: EXPERIMENTAL
Intervention: Strong social support for limiting dietary fat
Number of subjects: 1110

Group type: EXPERIMENTAL
Intervention: Change in social support over 12 months
Number of subjects: 1110

Group type: EXPERIMENTAL
Intervention: Baseline social support
Number of subjects: 1110

Group type: EXPERIMENTAL
Intervention: Social support by gender
Number of subjects: 1110
Study: 1620417

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg at 22 hours the night before surgery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg at 22 hours the night before surgery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg at 6 hours on the morning of surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (20 patients, no drugs)
Number of subjects: 60
Study: 6431812

Group type: EXPERIMENTAL
Intervention: Hydralazine therapy (100 mg orally every eight hours)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30709665

Group type: EXPERIMENTAL
Intervention: Cadazolid 250 mg twice daily with vancomycin-matching placebo capsule four times daily for 10 days
Number of subjects: 1263

Group type: COMPARATOR
Intervention: Vancomycin 125 mg four times a day with cadazolid-matching placebo suspension twice daily for 10 days
Number of subjects: 1263

Group type: EXPERIMENTAL
Intervention: Cadazolid 250 mg twice daily
Number of subjects: 1263

Group type: COMPARATOR
Intervention: Vancomycin 125 mg four times a day
Number of subjects: 1263
Study: 29523533

Group type: EXPERIMENTAL
Intervention: Oral acetaminophen (2 500-mg capsules before surgery)
Number of subjects: 486

Group type: COMPARATOR
Intervention: Intravenous acetaminophen (1,000 mg/100 mL during surgery)
Number of subjects: 486

Group type: COMPARATOR
Intervention: Intravenous acetaminophen
Number of subjects: 486
Study: 26739997

Group type: EXPERIMENTAL
Intervention: UMEC 500 µg
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: UMEC/VI 125/25 µg
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: UMEC/VI 500/100 µg
Number of subjects: 103

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 25129615

Group type: EXPERIMENTAL
Intervention: Set-back suture
Number of subjects: 42

Group type: COMPARATOR
Intervention: Buried vertical mattress suture (BVMS)
Number of subjects: 42
Study: 23544676

Group type: EXPERIMENTAL
Intervention: Synchronous tones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asynchronous tones
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alternating tones
Number of subjects: 0
Study: 20583396

Group type: EXPERIMENTAL
Intervention: 50 mg oral sildenafil + 40 microg beraprost
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 18236058

Group type: EXPERIMENTAL
Intervention: Praneem polyherbal pessary
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ginlac-V pessary
Number of subjects: 100
Study: 16770616

Group type: EXPERIMENTAL
Intervention: 1,000 mg ornidazole
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 14553835

Group type: EXPERIMENTAL
Intervention: Tuna fish oil
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173

Group type: COMPARATOR
Intervention: Oleic acid rich sunflower oil
Number of subjects: 173

Group type: COMPARATOR
Intervention: Evening primrose oil
Number of subjects: 173

Group type: COMPARATOR
Intervention: Soya bean oil
Number of subjects: 173

Group type: COMPARATOR
Intervention: Tuna/evening primrose oil mix
Number of subjects: 173
Study: 10974182

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg once daily
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg once daily
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg three times daily
Number of subjects: 67
Study: 9393572

Group type: EXPERIMENTAL
Intervention: Endoscopic laser therapy (ELT) only using a ND‐Yag Laser system (Group I and II)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Combined therapeutic regime with endocavitary Ir‐192 afterloading following ELT (Group III)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Endoscopic laser therapy (ELT) only (Group I and II)
Number of subjects: 81
Study: 8286230

Group type: EXPERIMENTAL
Intervention: 5% liquor carbonis detergens (LCD) in an emollient base
Number of subjects: 18

Group type: COMPARATOR
Intervention: Emollient base alone
Number of subjects: 18
Study: 2949417

Group type: EXPERIMENTAL
Intervention: Zoladex 500 micrograms/day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Zoladex 250 micrograms/day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Zoladex 3.6 mg once-monthly depot
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Zoladex (all dosages)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Zoladex
Number of subjects: 27
Study: 29771169

Group type: EXPERIMENTAL
Intervention: Zalutumumab
Number of subjects: 310
Study: 25614494

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 7621

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 7621
Study: 24986531

Group type: EXPERIMENTAL
Intervention: 75-g oral glucose tolerance test (OGTT) and three isocaloric (500 kcal) and isovolaemic (350 ml) liquid meals with varying fat content (2.5g, 10g, 40g)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-fat meals
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: OGTT and meals
Number of subjects: 30

Group type: COMPARATOR
Intervention: Patients with T2DM
Number of subjects: 30

Group type: COMPARATOR
Intervention: Incretin responses
Number of subjects: 30
Study: 22473217

Group type: EXPERIMENTAL
Intervention: Preventive consultation with a 3-month follow-up
Number of subjects: 495
Study: 19580467

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 2111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2111
Study: 17631335

Group type: EXPERIMENTAL
Intervention: Open label bacillus Calmette-Guerin
Number of subjects: 156

Group type: COMPARATOR
Intervention: Open label bacillus Calmette-Guerin (after initial placebo)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Open label bacillus Calmette-Guerin (after initial bacillus Calmette-Guerin)
Number of subjects: 156
Study: 15673388

Group type: EXPERIMENTAL
Intervention: Oral quinidine
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group (healthy normal subjects)
Number of subjects: 5
Study: 12045508

Group type: EXPERIMENTAL
Intervention: Posterolateral fusion (Group 1)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Posterolateral fusion combined with variable screw placement (Group 2)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Posterolateral fusion combined with variable screw placement and interbody fusion (Group 3)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: All surgical techniques (Groups 1, 2, and 3)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Nonsurgical group
Number of subjects: 222
Study: 8144735

Group type: EXPERIMENTAL
Intervention: 5% metronidazole collagen device
Number of subjects: 28

Group type: COMPARATOR
Intervention: Debridement
Number of subjects: 28
Study: 3343914

Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (HC) - 71% carbohydrate, isonitrogenous very-low-calorie diet (VLCD) of 2,219 kJ (530 kcal).d‐1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet (LC) - 33% carbohydrate, isonitrogenous very-low-calorie diet (VLCD) of 2,219 kJ (530 kcal).d‐1
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both HC and LC groups (supervised exercise sessions at 60% peak VO2, 3 times.wk‐1 for 30 to 45 min)
Number of subjects: 12
Study: 30579747

Group type: EXPERIMENTAL
Intervention: L-PRF
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: L-PRF + HA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 27689320

Group type: EXPERIMENTAL
Intervention: Supramaximal sprint time trials (STT 1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Supramaximal sprint time trials (STT 4)
Number of subjects: 10
Study: 26033332

Group type: EXPERIMENTAL
Intervention: Combined video feedback with audience feedback (VF + AF)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Video feedback only (VF)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Audience feedback only (AF)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 41
Study: 23580100

Group type: EXPERIMENTAL
Intervention: Health promotion intervention
Number of subjects: 0
Study: 21598890

Group type: EXPERIMENTAL
Intervention: Perioperative intra-articular injection of morphine, bupivacaine with epinephrine, and ketorolac
Number of subjects: 30

Group type: COMPARATOR
Intervention: Injectable sterile saline (control)
Number of subjects: 30
Study: 19667286

Group type: EXPERIMENTAL
Intervention: BAL8557 (100 mg isavuconazole) intravenous administration
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: BAL8557 (100 mg isavuconazole) oral administration
Number of subjects: 48
Study: 16449476

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Continuation treatment (up to 1 year)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Overall antidepressant response
Number of subjects: 159
Study: 16285312

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with methylaminooxopentanoate (Metvix) and a broad band light source (PhotoDyn 501)
Number of subjects: 28
Study: 11182341

Group type: EXPERIMENTAL
Intervention: Topiglan (1% alprostadil)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 60
Study: 9383357

Group type: EXPERIMENTAL
Intervention: Operative stabilization (OS)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Nonoperative treatment (NT)
Number of subjects: 133
Study: 8235691

Group type: EXPERIMENTAL
Intervention: Fludarabine (FDB)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Cyclophosphamide/Doxorubicin/Prednisone (CAP)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Cyclophosphamide/Doxorubicin/Prednisone (CAP) in stage C CLL
Number of subjects: 262

Group type: COMPARATOR
Intervention: Fludarabine (FDB) in stage C CLL
Number of subjects: 262

Group type: COMPARATOR
Intervention: Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP) in stage C CLL
Number of subjects: 262
Study: 3392892

Group type: EXPERIMENTAL
Intervention: Etomidate 2.5 mg/h
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Etomidate 0.3 mg/kg/h
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 6
Study: 30659665

Group type: EXPERIMENTAL
Intervention: Euhydrated (EUH)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Hypohydrated (HYP)
Number of subjects: 11
Study: 27490066

Group type: EXPERIMENTAL
Intervention: ASHRAE 62.2‐2010
Number of subjects: 81

Group type: COMPARATOR
Intervention: ASHRAE 62‐1989
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both groups (ASHRAE 62.2‐2010 and ASHRAE 62‐1989)
Number of subjects: 81